CTOs on the Move

Axial Biotherapeutics

www.axialbiotherapeutics.com

 
Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and Central Nervous System to develop a new class of therapeutics to improve the quality of life for people with CNS diseases and disorders
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Axial Biotherapeutics raised $19.5M on 11/30/2016
Axial Biotherapeutics raised $25M on 02/27/2019

Similar Companies

Genome Atlantic

Genome Atlantic is a Halifax, NS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Health Quality Council

Health Quality Council is a Saskatoon, SK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Tri State Surgical Supply

Tri State Surgical Supply is a Brooklyn, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Western Biomedical Enterprises

Western Biomedical Enterprises is a Placentia, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Provention Bio

Provention Bio, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics aimed at intercepting and preventing immune-mediated diseases. -We seek technologies or targets designed to predict, preempt or intervene before immune disease begins, re-appears or progresses. -We are creating a new biopharmaceutical category for autoimmunity. We leverage a transformational drug development strategy that sources, repositions and advances candidates that: -Target the interception or prevention of immune-mediated disease -Have been underdeveloped or deprioritized because of insufficient clinical trial efficacy or for strategic reasons -Have demonstrated proof-of-mechanism by preventing or intercepting immunopathologic pathways We believe that our deep understanding of immune-mediated pathophysiology, experience in translational medicine, and expertise in the design of rapid go/no-go clinical trials enables us to identify and evaluate potential therapeutic candidates for acquisition or in-licensing.